Skip to main content
Pelthos Therapeutics Inc.Form D offering

Pelthos Therapeutics Inc. filed a Form D with the SEC, reporting $57.5M sold, of a $57.5M offering.

What happened

Pelthos Therapeutics Inc. develops and commercializes innovative dermatology therapies, including products for molluscum contagiosum and other skin-health needs. This Form D reports a cash raise of $57.5 million from 7 investors, which signals meaningful capital behind commercialization and makes the company relevant for vendors selling into a growing pharmaceutical operator.

Source

Extracted by Autobound

From the Signal API record
Signal
Form D offering

What this signalsNew funding often brings new budget and vendor reviews.

Amount
$57.5M
Industry group
Pharmaceuticals
Headquarters
Durham, NC
Location
Durham, NORTH CAROLINA
Filed
Nov 16, 2026
Jurisdiction
Nevada

More form D offering signals at other companies

The full record

From the Signal API record

People

  • Scott PleshaExecutive Officer, Director · Named in the filing
  • John GayExecutive Officer · Named in the filing
  • Sai RangaraoExecutive Officer · Named in the filing
  • Richard BaxterDirector · Named in the filing
  • Peter GreenleafExecutive Officer, Director · Named in the filing
  • Ezra FriedbergDirector · Named in the filing
  • Todd DavisDirector · Named in the filing
  • Richard MalamutDirector · Named in the filing

Numbers

Amount (USD)
$57.5M
Investors
7

Details

CIK
0001919246
SIC code
2836
Form
D
Entity type
Corporation
Primary topic
Biotech Fundraise
Revenue range
Decline to Disclose
Business state
NC
Accession number
0001919246-26-000142
Resolved entity type
Operating company
Has non accredited investors
No
Filer
Pelthos Therapeutics Inc.
Resolved name
Pelthos Therapeutics

Topics and mentions

Topics

  • Pharmaceuticals
  • Commercial-stage
  • Dermatology
  • Private Placement
  • Healthcare Sales

Exemptions

  • 06b

Securities

  • Equity
  • OptionToAcquire
  • SecurityToBeAcquired

Extraction

Confidence
High
Relevance
80%
Detected
Nov 16, 2026
signal_type
sec-form-d-funding
signal_subtype
newFilingCompany

Use this data

Get every form D offering signal for Pelthos Therapeutics Inc. and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Pelthos Therapeutics Inc. this week?”

  2. Send it to your own tools

    The Signal API returns form D offering signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-form-d-funding record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/fd-0001919246-26-000142 returns this record as JSON. POST /v1/companies/enrich returns every signal for pelthos.com.

{
  "signal_id": "fd-0001919246-26-000142",
  "signal_type": "sec-form-d-funding",
  "signal_subtype": "newFilingCompany",
  "detected_at": "2026-11-16T00:00:00+00:00",
  "company": {
    "name": "Pelthos Therapeutics Inc.",
    "domain": "pelthos.com"
  },
  "data": {
    "cik": "0001919246",
    "phone": "919-908-2400",
    "detail": "The filing suggests a company beyond pure research, with commercial products and a focus on expanding therapies for unmet dermatology needs. A $57.5 million cash raise typically supports go-to-market execution, product development, and operating scale, so vendors should watch for spend in commercialization, regulatory/compliance, medical affairs, sales enablement, and enterprise infrastructure.",
    "topics": [
      "Pharmaceuticals",
      "Commercial-stage",
      "Dermatology",
      "Private Placement",
      "Healthcare Sales"
    ],
    "summary": "Pelthos Therapeutics Inc. develops and commercializes innovative dermatology therapies, including products for molluscum contagiosum and other skin-health needs. This Form D reports a cash raise of $57.5 million from 7 investors, which signals meaningful capital behind commercialization and makes the company relevant for vendors selling into a growing pharmaceutical operator.",
    "website": "https://pelthos.com",
    "location": "Durham, NORTH CAROLINA",
    "sic_code": "2836",
    "file_date": "2026-11-16",
    "form_type": "D",
    "relevance": 0.8,
    "confidence": "high",
    "exemptions": [
      "06b"
    ],
    "filing_url": "https://www.sec.gov/Archives/edgar/data/1919246/000191924626000142/",
    "source_url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001919246&type=D&dateb=&owner=include&count=40",
    "entity_name": "Pelthos Therapeutics Inc.",
    "entity_type": "Corporation",
    "jurisdiction": "NEVADA",
    "primary_topic": "Biotech Fundraise",
    "revenue_range": "Decline to Disclose",
    "business_state": "NC",
    "industry_group": "Pharmaceuticals",
    "related_persons": [
      {
        "name": "Scott Plesha",
        "email": "s***@pelthos.com",
        "roles": [
          "Executive Officer",
          "Director"
        ],
        "linkedin_url": "https://www.linkedin.com/in/scott-plesha-63ba50b3"
      },
      {
        "name": "John Gay",
        "roles": [
          "Executive Officer"
        ]
      },
      {
        "name": "Sai Rangarao",
        "email": "s***@pelthos.com",
        "roles": [
          "Executive Officer"
        ],
        "linkedin_url": "https://www.linkedin.com/in/sai-rangarao-88635122"
      },
      {
        "name": "Richard Baxter",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Peter Greenleaf",
        "roles": [
          "Executive Officer",
          "Director"
        ]
      },
      {
        "name": "Ezra Friedberg",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Todd Davis",
        "roles": [
          "Director"
        ]
      },
      {
        "name": "Richard Malamut",
        "roles": [
          "Director"
        ]
      }
    ],
    "total_investors": 7,
    "accession_number": "0001919246-26-000142",
    "securities_types": [
      "Equity",
      "OptionToAcquire",
      "SecurityToBeAcquired"
    ],
    "business_location": "Durham, NC",
    "total_amount_sold": 57500000,
    "resolved_entity_name": "Pelthos Therapeutics",
    "resolved_entity_type": "operating_company",
    "total_offering_amount": 57500000,
    "company_domain_confidence": 10,
    "has_non_accredited_investors": false
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.